PL2082225T3 - Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację - Google Patents

Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację

Info

Publication number
PL2082225T3
PL2082225T3 PL07823920T PL07823920T PL2082225T3 PL 2082225 T3 PL2082225 T3 PL 2082225T3 PL 07823920 T PL07823920 T PL 07823920T PL 07823920 T PL07823920 T PL 07823920T PL 2082225 T3 PL2082225 T3 PL 2082225T3
Authority
PL
Poland
Prior art keywords
invasive
determine whether
tumour cell
modulating agents
metastatic potential
Prior art date
Application number
PL07823920T
Other languages
English (en)
Inventor
Mohamed K El-Tanani
Patrick Gerard Johnston
Original Assignee
Univ Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0618486.5A external-priority patent/GB0618486D0/en
Priority claimed from GB0625379A external-priority patent/GB0625379D0/en
Application filed by Univ Belfast filed Critical Univ Belfast
Publication of PL2082225T3 publication Critical patent/PL2082225T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07823920T 2006-09-20 2007-09-20 Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację PL2082225T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0618486.5A GB0618486D0 (en) 2006-09-20 2006-09-20 Assay
GB0625379A GB0625379D0 (en) 2006-12-20 2006-12-20 Assay
EP07823920.9A EP2082225B1 (en) 2006-09-20 2007-09-20 Method to determine whether a tumour cell has invasive and/or metastatic potential and modulating agents of malignant transformation
PCT/GB2007/003599 WO2008035096A1 (en) 2006-09-20 2007-09-20 Assay

Publications (1)

Publication Number Publication Date
PL2082225T3 true PL2082225T3 (pl) 2014-06-30

Family

ID=38988374

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07823920T PL2082225T3 (pl) 2006-09-20 2007-09-20 Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację

Country Status (7)

Country Link
US (1) US8609332B2 (pl)
EP (1) EP2082225B1 (pl)
DK (1) DK2082225T3 (pl)
ES (1) ES2453374T3 (pl)
PL (1) PL2082225T3 (pl)
PT (1) PT2082225E (pl)
WO (1) WO2008035096A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
EP3688020A4 (en) * 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
GB201915598D0 (en) 2019-10-28 2019-12-11 Univ Bradford Methods for determining the invasive and/or metastic potential of a tumour

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613534B2 (en) * 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
WO2005032495A2 (en) * 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US7521195B1 (en) * 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof

Also Published As

Publication number Publication date
EP2082225B1 (en) 2014-01-01
ES2453374T3 (es) 2014-04-07
WO2008035096A1 (en) 2008-03-27
US8609332B2 (en) 2013-12-17
EP2082225A1 (en) 2009-07-29
PT2082225E (pt) 2014-04-10
US20090312395A1 (en) 2009-12-17
DK2082225T3 (da) 2014-04-07

Similar Documents

Publication Publication Date Title
PL2082225T3 (pl) Sposób określania czy komórka nowotworowa ma potencjał inwazyjny i/lub metastatyczny oraz środki modulujące złośliwą transformację
EP2291553A4 (en) SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
ZA201004326B (en) Methods and agents for improving targeting of cd138 expressing tumor cells
AP2010005186A0 (en) Method for the production of humus-and nutrient -rich and water-storing soils or soil substrates forsustainable land use and development systems
EP2142673A4 (en) NUCLEIC ACID GENES AND COMPLEXES AND METHOD OF USE THEREOF
ZA201105445B (en) Micronutrient fertilizers and methods of making and using the same
IL232786A0 (en) Inhibitors of e1 enzyme activators
WO2008086478A8 (en) Methods and compositions for identification of prostate cancer markers
GB0823091D0 (en) Exfoliating vermiculite and other minerals
EP1937815A4 (en) METHOD AND COMPOSITIONS FOR MODULATING TUMOR CELL ACTIVITY
IL200767A0 (en) Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents
EP2015782A4 (en) COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
IL206990A0 (en) Detection of gstp1 hypermethylation in prostate cancer
IL211994A0 (en) Prostate stem cells and uses thereof
GB2460009B (en) Compounds and methods for the modulation of beta-1 integrin function to mediatetissue repair
EP2023925A4 (en) CDKI PATH HEMMER AS SELECTIVE TEMPORARY GROWTH INHIBITORS
GB2443436B (en) Method of determing properties of the earth using turning wave data
EP2212874A4 (en) DEVICE FOR MONITORING AND LOCATING SEMI-TRAILERS
EP1994163A4 (en) INHIBITION OF THE GROWTH OF BREAST CARCINOMA STEM CELLS AND METASTASES
GB0624570D0 (en) Floating port and method of use
WO2012018982A3 (en) Methods and kits for modulating tumor invasiveness and metastatic potential
GB0605685D0 (en) Inhibition of tumour growth
IL201412A0 (en) Changes of forward-link and revers-link serving access points
GB0812708D0 (en) RF switchiing telemetry system and method
SI1786901T1 (sl) Inozitol polifosfat 2-kinazni geni in njihove uporabe